[Use of furamag to prevent inflammatory complications during endoscopic operations in patients with benign prostatic hyperplasia and urolithiasis].

Aim: To improve surgical results in patients with benign prostatic hyperplasia (BPH) and urolithiasis (UL) and to evaluate the efficacy of Furamag used as an agent to prevent infectious and inflammatory complications.

Subjects And Methods: Seventy-two patients with BPH (n = 36; Group 1) and UL (n = 36; Group 2) were examined. Within each group, the patients were divided into two subgroups: A) those in whom no preventive measures were taken during endoscopic operations; B) those who received Furamag as a preventive agent.

[Administration of afala preparation in urological practice].

Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination. Effect of this drug is seen in 98.3% patients during 4 weeks of its use.